An interventional study of Shatavari Root Extract, oral capsule in D008593, sponsored by Jacksonville University. Not yet recruiting at 1 site in United States. Open to female participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-23.
Sponsored by Jacksonville University · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to learn if a daily nutritional supplement can reduce hot flashes and other menopausal symptoms in postmenopausal women.
The main questions this study aims to answer are:
Does the supplement reduce the number and severity of daily hot flashes?
Does it improve other common menopausal symptoms?
Researchers will compare the supplement to a placebo (a look-alike capsule with no active ingredients) to see if it helps manage symptoms during menopause.
Participants will:
Take either the supplement or a placebo daily for 30 days
Track their hot flashes each day using a short online survey
Complete a symptom questionnaire at the beginning and end of the study
This study is for women ages 40-60 who have been postmenopausal for at least one year and currently experience bothersome hot flashes.
Purpose:
To evaluate the effectiveness of a nutritional supplement in reducing hot flash severity/frequency and menopausal symptoms in postmenopausal women.
Design:
Randomized, double-blind, placebo-controlled, two-arm, parallel-group trial over 30 days.
Participants:
Women aged 40-60 who are postmenopausal (≥1 year without menses) and report bothersome hot flashes (Menopause Rating Scale score ≥14, and hot flash severity of 3 or 4).
Exclusion Criteria:
Current hormone therapy or medications affecting hot flashes; significant comorbidities.
Intervention:
Group 1: Placebo
Group 2: Supplement
Assessments:
Daily self-reports of hot flash frequency/severity
Menopausal symptom assessments at baseline (Day 0) and post-intervention (Day 30)
Outcomes:
Primary: Hot flash severity and frequency
Secondary: Overall menopausal symptoms
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
This study's planned enrollment of 44 is below the median of 90 across 306 interventional studies indexed under Hot Flashes.
Browse Hot Flashes studies →Jacksonville University is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dietary Supplement: Shatavari Root Extract, oral capsule
Dietary Supplement: Shatavari Root Extract, oral capsule
This intervention consists of a proprietary, standardized extract of Asparagus racemosus (Shatavari), formulated specifically for women's health and cognitive support. The supplement is provided in oral capsule form and standardized to a specific concentration of shatavarin IV, the primary active compound. Participants will take one capsule daily for 30 days. This formulation, known as SheVari4™, is patent-pending and manufactured by Cepham, designed to address vasomotor symptoms (hot flashes) and other menopausal concerns. It is distinct from other Shatavari supplements in its standardization and use in a placebo-controlled, double-blind trial targeting postmenopausal women.
Composite hot flash score: Frequency × Severity
Frequency: Total number of hot flashes experienced that day. Hot Flash Severity: Rating of hot flashes on a 7-point severity scale (0 = none, 1 = very mild, 2 = mild, 3 = mild/moderate, 4 = moderate, 5 = severe, 6 = very severe)
Time frame: 30 days
Menopause Rating Scale
Validated self-administered questionnaire consisting of 11 items that assesses menopausal symptoms. Each item is rated on a 5-point Likert scale from 0 (not present) to 4 (very severe), yielding a total score range of 0 to 44, with higher scores indicating more severe symptoms. The Menopause Rating Scale is divided into three domains: somatic (hot flashes, heart discomfort, sleep problems, joint and muscular discomfort), psychological (depressive mood, irritability, anxiety, physical and mental exhaustion), and urogenital (sexual problems, bladder problems, vaginal dryness). This scale has been widely used in clinical research to quantify menopausal symptom burden and its impact on quality of life.
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jacksonville University